Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Followed by Sunitinib for High Risk Non-muscle Invasive Bladder Cancer
NCT00794950Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Jan 2009
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in urothelial carcinoma (UC), sponsored by University of Michigan. Primary endpoint: Complete Response at 3 months. Started Jan 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00794950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00794950.